SCHEMBL3120899

SCHEMBL3120899

CCCCCCCCCCCCCCNS(=O)(=O)NCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 1.00
CA1 P00915 5/20 0.73
CA2 P00918 5/20 0.73
CA12 O43570 3/20 0.73
CA14 Q9ULX7 3/20 0.73
CA7 P43166 2/20 0.73
CA9 Q16790 1/20 0.61
EPHX1 P07099 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3117611 1.00 PPARA (1.00) PPARACA1CA2CA12CA14
SCHEMBL18644318 1.00 PPARA (1.00) PPARACA1CA2CA12CA14
SCHEMBL3119510 1.00 PPARA (1.00) PPARACA1CA2CA12CA14
SCHEMBL10892940 0.95 PPARA (0.91) PPARACA1CA2CA12CA14
SCHEMBL9285865 0.95 PPARA (0.91) PPARACA1CA2CA12CA14
SCHEMBL3792249 0.95 PPARA (0.91) PPARACA1CA2CA12CA14
SCHEMBL4563383 0.93 PPARA (0.86) PPARACA1CA2CA12CA14
SCHEMBL3803009 0.88 PPARA (0.79) PPARACA1CA2CA12CA14
SCHEMBL3114654 0.88 PPARA (1.00) PPARACA1CA2CA12CA14
SCHEMBL3119679 0.88 PPARA (1.00) PPARACA1CA2CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984326-B1 ACYCLIC SULFAMIDE DERIVATIVES FUND IMABIS INST MEDITTERANEO PARA EL AVAN E DE LA BIOTECNOLOGIA Y LA INVESTIG SANITARIA (ES) 2017-05-03 EP claimed
US-8188312-B2 Acyclic sulfamide derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2012-05-29 US claimed
US-20100179224-A2 Acyclic Sulfamide Derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2010-07-15 US claimed
US-20100048712-A2 Acyclic Sulfamide Derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2010-02-25 US claimed
US-20090221710-A1 Acyclic Sulfamide Derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2009-09-03 US claimed
EP-1984326-A1 ACYCLIC SULFAMIDE DERIVATIVES Fundacion Imabis. Inst. Meditteraneo para el Avan e de la Biotecnologia y la Investigacion Sanitaria (ES) 2008-10-29 EP claimed
WO-2007085469-A1 ACYCLIC SULFAMIDE DERIVATIVES FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2007-08-02 WO claimed
EP-1984326-B1 ACYCLIC SULFAMIDE DERIVATIVES FUND IMABIS INST MEDITTERANEO PARA EL AVAN E DE LA BIOTECNOLOGIA Y LA INVESTIG SANITARIA (ES) 2017-05-03 EP disclosed
US-8188312-B2 Acyclic sulfamide derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2012-05-29 US disclosed
US-20100179224-A2 Acyclic Sulfamide Derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2010-07-15 US disclosed
US-20100048712-A2 Acyclic Sulfamide Derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2010-02-25 US disclosed
US-20090221710-A1 Acyclic Sulfamide Derivatives FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2009-09-03 US disclosed
EP-1984326-A1 ACYCLIC SULFAMIDE DERIVATIVES Fundacion Imabis. Inst. Meditteraneo para el Avan e de la Biotecnologia y la Investigacion Sanitaria (ES) 2008-10-29 EP disclosed
WO-2007085469-A1 ACYCLIC SULFAMIDE DERIVATIVES FUNDACION IMABIS. INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA (ES) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179224-A2 Acyclic Sulfamide Derivatives SULT2A1, STS, SUCNR1 PPARA 346/4885CA1 1840/4885CA2 1092/4885
US-20090221710-A1 Acyclic Sulfamide Derivatives STS, LIPE, FABP4 PPARA 30/4885CA1 3726/4885CA2 2198/4885
US-20100048712-A2 Acyclic Sulfamide Derivatives SULT2A1, STS, SUCNR1 PPARA 346/4885CA1 1840/4885CA2 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.